Segovia et al. [15] found that TMEM176B inhibitor (BayK8644) can promote CD8+ T cell-mediated tumor suppression and enhance anti-tumor activities of anti-CTLA-4 and anti-PD-1 antibodies. This evidence concerns the gene CD8A and neoplasm.